BEAT: A Heart-Felt Buy

05/10/2016 7:00 am EST


James Oberweis

President, Oberweis Asset Management, Inc.

Our latest featured small cap recommendation is a firm that provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services, notes Jim Oberweis, Jr., editor of The Oberweis Report.

BioTelemetry (BEAT) has developed a proprietary integrated patient management platform that incorporates a wireless data transmission network, FDA-cleared algorithms and medical devices, and 24-hour monitoring service centers.

The firm's healthcare segment, which generated 82% of revenue in 2015, is focused on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders.

The company offers cardiologists and electrophysiologists a full spectrum of solutions which provides them with a single source of cardiac monitoring services.

The firm's monitor service incorporates a lightweight, patient-worn sensor attached to electrodes that capture two-channel ECG data, measuring electrical activity of the heart, on a compact wireless handheld monitor.

The monitor analyzes incoming heartbeat-by-heartbeat information from the sensor on a real-time basis by applying proprietary algorithms designed to detect arrhythmias.

When the monitor detects an arrhythmic event, it automatically transmits the ECG to the monitoring centers.

At the monitoring centers, experienced certified cardiac monitoring specialists analyze the sent data, respond to urgent events and report results in the manner prescribed by the physician.

The device employs two-way wireless communications, allowing physicians to remotely adjust monitoring parameters and request previous ECG data from the memory stored in the monitor.

BioTelemetry reported earnings per share of $0.20 in the latest reported first quarter versus $.06 in the same quarter of last year.

Clients of Oberweis Asset Management own approximately 43,000 shares. These shares may be appropriate for risk oriented investors.

Subscribe to The Oberweis Report here.

By Jim Oberweis, Jr., Editor of The Oberweis Report

More from

Pharma Trio at the Forefront of Innovation

Glaxo: Bold Moves in Big Pharma

Split Portfolio Signs up Ensign

  By clicking submit, you agree to our privacy policy & terms of service.

Related Articles on STOCKS